Previous 10 | Next 10 |
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET. A live webcast can be...
Novartis (NYSE:NVS) is scheduled to announce Q4 earnings results on Wednesday, February 2nd, before market open. The consensus EPS Estimate is $1.44 (+7.5% Y/Y) and the consensus Revenue Estimate is $13.28B (+4.0% Y/Y). Over the last 2 years, NVS has beaten EPS estimates 75% of the time and h...
Industry Leaders Lend Scientific and Clinical Expertise to Several Board Committees BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and ac...
BRUKINSA was granted its first breakthrough therapy designation in China with this application The application is supported by SEQUOIA trial results, which demonstrated BRUKINSA’s superiority in efficacy over chemoimmunotherapy BRUKINSA received the China NMPA c...
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at incredible rates. According to Precedence Researc...
In the RATIONALE 305 trial, tislelizumab combined with chemotherapy prolonged overall survival for patients with PD-L1 expression Additional follow-up is needed to assess overall survival benefits in intention-to-treat patient population Safety findings of tislelizumab...
BRUKINSA received the China NMPA approval for the treatment of patients with relapsed or refractory Waldenström’s macroglobulinemia (WM) in June 2021 The submission, supported by the ASPEN trial results, could potentially expand BRUKINSA to front-line care of WM ...
Shares of Leap Therapeutics (NASDAQ: LPTX) , a clinical-stage biopharmaceutical company , are surging in response to positive clinical results from a stomach cancer study. Investors excited about the company's lead candidate, DKN-1, drove the stock 10.3% higher as of 12:55 p.m. ...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the J.P. Morgan 40th Annual Healthcare Conference on Tuesday, January 11, 2022 at 5:15 p.m. ET. A live webcast can be acces...
Tislelizumab is now approved in six indications in China This marks tislelizumab’s third approved lung cancer indication in China and first in a previously treated patient population The approval was supported by results from the global Phase 3 trial R...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...